Major malaria vaccine trial shows promise for african children
NCT ID NCT04704830
First seen Feb 24, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This large Phase 3 trial is testing whether the R21/Matrix-M vaccine can protect young children (5-36 months old) from getting malaria. About 4800 children in Africa are taking part. The study compares vaccinated children to those who did not get the vaccine to see if the shot safely reduces malaria cases over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.